FR901228 in Treating Patients With Relapsed or Refractory Advanced Ovarian Epithelial Cancer
Status:
Withdrawn
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
RATIONALE: FR901228 may stop the growth of tumor cells by blocking the enzymes necessary for
their growth.
PURPOSE: This phase II trial is studying how well FR901228 works in treating patients with
relapsed or refractory advanced ovarian epithelial cancer.